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survival	were	 found	outside	the	HLA	region.	We	discuss	 the	 implications	 for	 future	
research	and	clinical	application.




Kidney	 transplantation	 is	 a	 highly	 successful	 treatment	 for	 end-	
stage	 renal	 failure,	with	 significant	 benefits	 for	 recipients	 both	 in	
survival	and	quality	of	 life.	Early	outcomes	have	steadily	 improved	
over	 the	 last	10	years,1	with	 risk-	adjusted	and	death-	censored,	1-	
year	 renal	 graft	 survival	 rates	 of	 94%	 and	 97%	 for	 deceased	 and	
living donor transplants, respectively.2	However,	both	late	allograft	
loss	and	increased	mortality	among	transplant	recipients	remain	key	
challenges	 for	 the	 transplant	 community.	 There	 are	 a	 wide	 num-
ber	 of	 factors	 that	 are	 known	 to	 influence	 long-	term	 transplant	
outcome,	 including	 donor	 factors	 such	 as	 age	 and	 comorbidity,	
recipient	 factors	 such	 as	 comorbidity	 and	 response	 to	 immuno-
suppression,	as	well	as	allograft	 ischemic	 time,	 the	degree	of	HLA	
mismatch,	 and	 the	 development	 of	 donor-	specific	 antibodies.3-5 
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of	graft	failure	has	remained	elusive,	with	the	observed	variation	in	
patient	outcomes	still	inadequately	explained	by	our	current	under-




The	 importance	of	 genetic	 factors	 in	 transplantation	has	been	
clear	 since	 the	 inception	 of	 the	 technique,	with	 the	 first	 success-
ful	 kidney	 transplant	 having	 been	 performed	 between	 identical	
twins	 in	1954.	Renal	 transplantation	between	 identical	 twins	con-
tinues	 to	 show	 excellent	 long-	term	 outcomes,6,7	 and	HLA	match-
ing	has	a	 large	 impact	on	graft	survival	even	 in	the	modern	era	of	
immunosuppression.8
HLA	genes	are	highly	polymorphic,	 and	demonstrate	 the	 impor-
tance	of	genetic	variation	 in	donor-	recipient	pairing	that	 impacts	on	




ploring	 the	 association	 between	 genotypes	 of	 interest	 and	 renal	
transplant outcomes.9,10	A	 large	proportion	of	 these	studies	have	
concentrated	 on	 immune-	related	 genes,	 based	 on	 the	 hypoth-
esis	 that	 the	 risk	 of	 acute	 rejection	 or	 late	 allograft	 loss	may	 be	
modulated	by	genetic	variation	 in	 the	 immune	 response.	As	sum-
marized	 in	 Table	 S1,	 associations	 have	 been	 described	 between	
various	 transplant	 phenotypes	 and	 single	 nucleotide	 polymor-
phisms	 (SNPs)	 in	 a	 number	 of	 genes	 including	 those	 encoding	
tumor	necrosis	 factor-	α,	 interleukins-	1,	 -	6,	 and	 -	10,	 and	 interfer-




and	 recipient	 were	 associated	 with	 reduced	 graft	 survival.11,12 
While	 some	 of	 this	 discrepancy	 might	 be	 explained	 by	 method-
ological	 or	 populational	 differences	 between	 these	 studies,	 it	 is	
difficult	 to	draw	firm	conclusions	about	 the	 role	of	 these	genetic	 
variations.13
More	recently,	attention	has	also	focused	on	non-	immune-	related	
genetic	 risk	variants.	Donor	genetic	variation	 in	CAV1	 (caveolin-	1),14 
APOL1	(apolipoprotein-	L1),15,16 or ABCB1	(ATP-	binding	cassette,	sub-
family-	B,	 member-	1,	 expressed	 in	 the	 kidney)	 genes	 17,18	 has	 been	
reported	 to	 be	 associated	with	 increased	 risk	 of	 allograft	 failure	 or	




also	 impact	on	 transplant	outcomes	 such	 as	 increased	 risk	of	 acute	
rejection.19
In	 general,	 candidate	 gene	 studies	 in	 renal	 transplantation	 have	
so	 far	 failed	 to	 provide	 consistent	 and	 reproducible	 results.	 Some	
of	 the	 reasons	 for	 this	may	 include	 small	 sample	 sizes,	variations	 in	



















Transplant	 Consortium	 (UKIRTC;	 www.ukirtc.org).	 Collaborative	
initiatives	such	as	these	are	essential	for	the	collection	of	adequate	
sample	 numbers,	 for	 the	 sharing	 of	 expertise,	 standardization	 of	
techniques,	 and	 building	 consensus	 on	 accurate	 phenotyping	 of	
clinical	 data.	 Through	 this	 consortium,	 3936	 samples	 comprising	
2094	 complete	 donor-	recipient	 pairs	 were	 tested	 in	 the	 GWAS	
discovery	phase,	and	an	additional	5866	complete	donor-	recipient	
pairs	 in	the	replication	phase,	making	this	the	 largest	GWAS	con-





in	 partnership	with	 the	WTCCC-	3	 and	 the	National	 Health	 Service	
Blood	and	Transplant	database	(NHS-	BT),	sourced	all	available	good-	
quality	stored	DNA	samples	and	pre-	existing	GWAS	data	from	both	
recipients	 and	 their	 corresponding	 donors	 from	 all	 renal	 transplan-














and	 data	 referred	 to	 transplants	 that	 took	 place	 between	 December	
1981	and	December	2007.
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Inclusion	 criteria	 for	 the	 study	 were	 as	 follows:	 (1)	 deceased	
donor	kidney	transplants	only;	(2)	recipient	is	an	adult	(>16	years	old);	 
(3)	 reported	 European	 ancestry	 for	 recipients;	 and	 (4)	 graft	 survival	







Clinical	 variables,	 datasets,	 and	 analysis	 are	 described	 in	
Supplementary	Methods.










(using	Cox	proportional	 hazards	modeling)	 for	 (1)	 donor	SNP	genotype	
main	effects;	(2)	recipient	SNP	genotype	main	effects;	(3)	donor*recipient	
SNP	 genotype	 interaction	 effects	 (1df	 and	 3df	 tests);	 and	 (4)	 CNV-	 
	tag-	SNPs	genotype	mismatch	effects	 (2	different	models).	Acute	 rejec-










studies; WTCCC, Wellcome Trust Case Control Consortium
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replication	panel	of	139	SNPs	(post–quality	control)	was	tested	based	
on	a	 combination	of	 low	P	 value	 (<10−6)	 from	 the	discovery	phase,	
plus	 good	 support	 of	 association	 signals	 from	SNPs	 in	 local	 linkage	
disequilibrium	(LD),	or	on	prior	candidature	from	previous	association	
studies.	SNPs	were	tested	according	to	the	same	model	as	motivated	
their	 inclusion	 in	 the	 replication	 panel	 (for	 example,	 if	 nominated	
based	on	a	low	P	value	for	acute	rejection	in	recipients,	then	that	was	
also	the	test	of	 interest	 in	the	replication	analysis).	Meta-	analysis	of	
discovery	and	 replication	 results	was	carried	out	using	 inverse	vari-
ance	meta-	analysis.27
For	 further	 details	 see	Figure	1	 and	 the	Methods	 section	 in	 the	
Supplementary Material.






Despite	 the	 large	 size	 of	 our	 study	 (Table	1	 and	 Table	 S2),	
none	 of	 the	 phenotypes	 and	 genetic	 models	 tested	 in	 the	
TABLE  1  Indicative	renal	transplant	demographics	from	WTCCC3	and	the	validation	cohort.	For	consistency,	numbers	refer	to	transplants	
where	both	donors	and	recipients	passed	QC	(“complete”	donor-	recipient	pairs)
WTCCC3 (post QC) % Replication cohort %
Total	transplants	where	both	donors	and	
recipients passed QC
2094 100 5866 100
Total	unique	donors	with	a	paired	recipient 1850 100 5027 100
Total	unique	recipients	with	a	paired	donor 2086 100 5866 100
Mean donor age ± SD 43	±	15.4 43	±	16.7
Mean recipient age ± SD 45	±	13.3 48	±	13.6
0 previous grafts 1864 89 N/A
1 previous graft 204 9.7 N/A










0	HLA	mismatches 223 10.7 N/A
1	or	2	Class	I	HLA	mismatches 839 40.1 N/A
1	or	2	Class	II	HLA	mismatches 20 0.96 N/A
1	or	2	mixed	Class	I/II	HLA	mismatches 124 5.9 N/A
3	to	5	HLA	mismatches 612 29.2 N/A
6	HLA	mismatches 8 0.4 N/A
N/A	HLA	mismatches 268 12.8 N/A
Graft	survival:	total	uncensored 495 23.6 2951 50.3
Graft	survival:	total	censored 1599 76.4 2915 49.7
Total	double-	kidney	transplants 3 0.14 N/A
Total	en	bloc	kidney	transplants 1 0.05 N/A
Total	kidney+pancreas	transplants 16 0.76 N/A
Total	kidney-	only	transplants 2074 99.0 N/A
Total	rejections	(first	3	mo) 259 12.4 N/A
Total	no	rejections	(first	3	mo) 915 43.7 N/A
N/A	rejections	(first	3	mo) 920 43.9 N/A
Total	rejections	(3-	12	mo) 221 10.6 575 9.8
Total	no	rejections	(3-	12	mo) 946 45.2 2573 43.9
N/A	rejections	(3-	12	mo) 927 44.3 2718 46.3
N/A,	data	not	available;	QC,	quality	control;	WTCCC3,	Wellcome	Trust	Case	Control	Consortium-	3.
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discovery	 phase	 produced	 any	 LD-	supported	 single-	SNP	 re-
sults	of	 genome-	wide	 significance	 (P	≤	5	×	10−8).	We	also	per-
formed	a	partitioned	heritability	analysis	via	stratified	LD	score	
regression,28	which	 failed	 to	 reveal	 any	 significant	enrichment	
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pare	 recorded	 information	with	 imputed	mismatches	based	on	SNP	
genotype	 information	 (Figure	3).	 As	 expected	 for	 deceased	 donor	
transplants,	the	number	of	non-	zero	mismatch	transplants	in	our	data	
was	low,	reducing	our	power	to	detect	associations.	Nevertheless,	we	
confirmed	 significant	 associations	 with	 HLA-	A	 (P	=	.022)	 and	 HLA-	
DRB	(P	=	.00049)	mismatches	using	the	recorded	data.
On	the	other	hand,	the	imputed	mismatch	results	did	not	reproduce	
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to	 be	 reliably	 discovered.	With	 a	 few	 notable	 exceptions,33	 GWAS	
studies	on	other	traits	have	been	unsuccessful	in	discovering	reliable	
interaction effects.
Thirdly,	 and	 perhaps	 most	 importantly,	 the	 transplantation	 out-
comes	we	considered	were	relatively	crude	measures	obtained	retro-
spectively from national registry data, collected over many years for 
reasons	other	 than	 for	 acting	 as	 endpoints	 in	 a	 genome-	wide	 asso-
ciation	 study.	Our	outcomes	were	 therefore	heterogeneous,	 subject	
to	missingness,	and	subject	to	environmental	factors	that	likely	weak-
ened	 the	genetic	 signals.	Graft	 survival	 time	 is	expected	 to	be	 sub-
ject	to	a	range	of	factors	including	graft	quality,	drug	regimen,	patient	
compliance,	 changes	 in	 standard-	of-	care	 over	 time,	 between-	center	
differences,	 and	 underlying	 biological	 causes	 of	 renal	 dysfunction.	
Additionally,	a	 substantial	proportion	of	 the	survival	 time	data	were	
right-	censored	 (60.5%-	76.4%,	depending	on	model	being	 fitted),	 re-
ducing	the	power	for	this	endpoint.
Acute	graft	rejection	is	also	a	heterogeneous	phenotype	arising	from	






note	 the	nonrandom	missingness	bias	would	need	to	be	 the	same	 in	
both	the	discovery	and	replication	cohorts	for	a	signal	to	be	replicated).
Batch	effects	are	also	a	concern.	Both	the	discovery	and	replica-
tion	data	were	obtained	 from	multiple	 different	 collection	points	 in	
different	countries	over	many	years,	and	thus	our	phenotypes	may	be	
subject	to	batch	effects,	for	example,	arising	from	different	treatment	






the	 same	 in	both	 the	discovery	 and	 replication	 cohorts	 in	order	 for	








signals	 at	HLA-	A	 and	HLA-	DRB.	This	 suggests	 that	 the	 accuracy	of	
HLA	imputation	will	need	to	be	improved	before	it	can	be	used	reliably	












These	 indicated	 that	we	were	well	 powered	 to	detect	 any	main	 ef-
fect	 graft	 survival	 association	 signals	 involving	 causal	 SNPs	 with	
allelic	 hazard	 ratios	 in	 the	 range	 1.4-	1.9	 (log-	additive	 risk	 model,	







nals	 outside	 of	 the	HLA	 region.	 Both	 phenotype	 heterogeneity	 and	
sample	 size	may	have	 contributed	 to	 this	 result.	 Looking	 ahead,	we	
note	that	the	general	lessons	from	GWAS	applied	to	multiple	human	
traits	 over	 more	 than	 a	 decade	 have	 brought	 home	 3	 clear	 mes-
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